The MHRA has approved a new high-dose version of Wegovy injection containing 7.2mg of semaglutide, which is three times the current standard dose of 2.4mg available on the NHS[1]. This higher dose is intended for obese adults (BMI 30 and above) who have not achieved sufficient weight loss after at least four weeks of taking the standard dose[1]. Clinical trials showed that the high-dose version achieved 20.7% weight loss compared to 2.4% for placebo after 72 weeks, with a third of participants losing 25% or more of their body weight[1]. The safety profile of the high-dose version was comparable to the standard dose, with adverse effects mostly mild to moderate[1]. Novo Nordisk plans to launch this dose this year[1]. It will have to undergo a cost-effectiveness review by NICE[1] before being approved for the NHS.